~~<i id='4F19932C14'><strike id='4F19932C14'><tt id='4F19932C14'><pre id='4F19932C14'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：explore 2025-10-02 20:59:46 - browse：765

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Average age of first period drops to 11.9 years, study shows

hotspot

focus

Wikipedia

focus

hotspot

leisure time

2:13FILE-TheburnedremainsofahomedestroyedbytheMarshallFireareshown,Jan.7,2022,inLouisville,Colo.OnTh

WSS

New research casts further doubt on a common procedure used with IVF

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Charles Manson follower Leslie Van Houten released from prison after 53 years

Bulgari apologizes to China for listing Taiwan as a country after online backlash

How the political right came to back psychedelics to treat trauma

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

knowledge

focus

hotspot

The high cost of giving birth even with insurance

Heat waves linked to early deliveries, preterm births in new study

Moonlake's readout produced a cash windfall. Risks remain

First Opinion Podcast: What happens when kids become caregivers?

Medical records are filled with copy

Study: Pain burden is higher in Black NFL players than white ones

Affirmative action in medical school literally saved lives

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Hepatitis C has a cure — but many Americans still lack access to it

HCA discloses massive data breach affecting 11 million patients

focus

David Sabatini, ex

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Oak trusses raised to roof of fire

Do more moles mean more problems? Not so, says new study

Latest bird flu infection made farmworker sicker than earlier cases

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Wikipedia

focus

hotspot

leisure time